Orexin B is a neuropeptide from the hypocretin family that has been studied in the laboratory for its role in regulating wakefulness, appetite, metabolism, and stress response. The form in this product is for research purposes only.
Active ingredient content
5 mg
Concentration (test)
Unspecified
Packaging
Glass bottle with sterile cap
Storage
2–8 °C, away from light
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
Hypocretin 2, Orexin-B
In laboratory conditions, Orexin B is mainly studied in relation to:
- regulating the sleep-wake cycle,
- by modulating appetite and food intake,
- affecting alertness and energy levels,
- stress response and emotional reactivity,
- neurological research into narcolepsy and mood disorders.
This content is for educational purposes only. It is not intended for human use. It does not apply to intravenous administration.
What is Orexin B?
Orexin B, also known as hypocretin-2, is a peptide neurotransmitter produced in the lateral hypothalamus. Together with its relative Orexin A, it plays a key role in the regulation of wakefulness, energy homeostasis, and emotional behavior. Experiments have investigated its action on OX2 receptors, which are distributed mainly in the brainstem and limbic system.
How Orexin B works
Orexin B activates OX2 receptors, promoting wakefulness, increasing stress hormone levels, and influencing the autonomic nervous system. Unlike Orexin A, it has a higher selectivity for OX2, making it interesting for research into sleep disorders, depression, and metabolic regulation. Studies show that injection of Orexin B can affect the activity of neuronal circuits in the hypothalamus, amygdala, and thalamus.
Effects studied
-
Promotes wakefulness: stimulation of OX2 receptors increases wakefulness in animal models.
-
Increase in appetite: orexins play a significant role in regulating hunger and satiety.
-
Stress modulation: affects cortisol levels and behavior in stress models.
-
Depression research: observed impact on emotional centers of the brain (amygdala, hippocampus).
-
Neuroprotection: presumed effects on protecting nerve cells from degeneration.
Dosage in studies
-
Study (rat model): intracerebral application of 3 μg Orexin B into the lateral hypothalamus for behavioral observation.
-
Study (mice): 5 μg/kg subcutaneously, aimed at monitoring the sleep/wake cycle.
-
Study (behavioral tests): 2 μg injected into the amygdala to modulate stress response.
Dosage information is based solely on preclinical studies. The product is not approved for human use.
Possible side effects
In animal studies, changes in blood pressure, anxiety, hyperactivity, and changes in heart rate have been observed. No serious neurotoxic effects have been reported, but short-term behavioral abnormalities have been observed with intracerebral applications. The safety of subcutaneous or intramuscular administration is still under investigation.
This content is for research and laboratory use only. Do not exceed recommended limits for preclinical testing. Not suitable for intravenous administration.
Resources
- Sakurai T et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and their receptors.
- Chen L et al. (2006). Role of orexin-B in arousal and feeding regulation: neuropharmacological evidence.
- Winrow CJ et al. (2011). Targeting orexin signaling pathways in sleep and mood disorders.
For research purposes only. The product is not intended for the diagnosis, treatment or prevention of disease.
Sale
Sale
